293 related articles for article (PubMed ID: 26769007)
21. T-Score Discordance of Bone Mineral Density in Patients with Atypical Femoral Fracture.
Lee KJ; Min BW; Song KS; Bae KC; Cho CH; Lee SW
J Bone Joint Surg Am; 2017 Oct; 99(19):1683-1688. PubMed ID: 28976433
[TBL] [Abstract][Full Text] [Related]
22. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.
Eisenstein N; Kasavkar G; Bhavsar D; Khan FS; Paskins Z
BMC Musculoskelet Disord; 2017 Jan; 18(1):29. PubMed ID: 28114975
[TBL] [Abstract][Full Text] [Related]
23. A proposal for an atypical femur fracture treatment and prevention clinical practice guideline.
Dell R; Greene D
Osteoporos Int; 2018 Jun; 29(6):1277-1283. PubMed ID: 29675745
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of bisphosphonate and non-bisphosphonate related atypical femoral fracture in a South East Asian population - Secondary analysis.
Gani LU; Anthony NF; Dacay LM; Tan PT; Chong LR; King TFJ
Bone; 2022 Sep; 162():116455. PubMed ID: 35688361
[TBL] [Abstract][Full Text] [Related]
25. Critical differences between subtrochanteric and diaphyseal atypical femoral fractures: analyses of 51 cases at a single institution in Korean population.
Cho YJ; Kang KC; Chun YS; Rhyu KH; Kim SJ; Jang TS
Arch Osteoporos; 2018 May; 13(1):53. PubMed ID: 29725835
[TBL] [Abstract][Full Text] [Related]
26. Incidence of atypical nontraumatic diaphyseal fractures of the femur.
Dell RM; Adams AL; Greene DF; Funahashi TT; Silverman SL; Eisemon EO; Zhou H; Burchette RJ; Ott SM
J Bone Miner Res; 2012 Dec; 27(12):2544-50. PubMed ID: 22836783
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis.
Wong CH; Kan AKC; Tsoi KH; Chan SSY; Jiang NS; Loong CHN; Fong CHY; Wong JSH; Shea GKH; Cheung CL; Lee CH; Tan KCB; Woo YC; Lui DTW
Endocrine; 2024 Apr; 84(1):223-235. PubMed ID: 37985574
[TBL] [Abstract][Full Text] [Related]
28. [Atypical femoral fractures due to the use of bisphosphonates. Experience of two institutions].
Villegas RI; Melo-Durán S; Cevallos A; Barros-Prieto EA
Acta Ortop Mex; 2023; 37(5):270-275. PubMed ID: 38382451
[TBL] [Abstract][Full Text] [Related]
29. Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates.
Watts NB; Aggers D; McCarthy EF; Savage T; Martinez S; Patterson R; Carrithers E; Miller PD
J Bone Miner Res; 2017 May; 32(5):1027-1033. PubMed ID: 28071822
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy.
Franceschetti P; Bondanelli M; Caruso G; Ambrosio MR; Lorusso V; Zatelli MC; Massari L; Degli Uberti EC
Bone; 2013 Oct; 56(2):426-31. PubMed ID: 23871850
[TBL] [Abstract][Full Text] [Related]
31. Assessment of femur geometrical parameters using EOS™ imaging technology in patients with atypical femur fractures; preliminary results.
Morin SN; Wall M; Belzile EL; Godbout B; Moser TP; Michou L; Ste-Marie LG; de Guise JA; Rahme E; Brown JP
Bone; 2016 Feb; 83():184-189. PubMed ID: 26541215
[TBL] [Abstract][Full Text] [Related]
32. The Epidemiology of Metatarsal Fractures Among Older Females With Bisphosphonate Exposure.
West TA; Pollard JD; Chandra M; Hui RL; Weintraub MR; King CM; Grimsrud CD; Lo JC
J Foot Ankle Surg; 2020; 59(2):269-273. PubMed ID: 32130989
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ;
N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571
[TBL] [Abstract][Full Text] [Related]
34. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
Adler RA; El-Hajj Fuleihan G; Bauer DC; Camacho PM; Clarke BL; Clines GA; Compston JE; Drake MT; Edwards BJ; Favus MJ; Greenspan SL; McKinney R; Pignolo RJ; Sellmeyer DE
J Bone Miner Res; 2016 Jan; 31(1):16-35. PubMed ID: 26350171
[TBL] [Abstract][Full Text] [Related]
35. Bone cross-sectional geometry is not associated with atypical femoral fractures in Asian female chronic bisphosphonate users.
Chou AC; Ng AC; Png MA; Chua DT; Ng DC; Howe TS; Koh JS
Bone; 2015 Oct; 79():170-5. PubMed ID: 26067179
[TBL] [Abstract][Full Text] [Related]
36. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.
Hagen JE; Miller AN; Ott SM; Gardner M; Morshed S; Jeray K; Alton TB; Ren D; Abblitt WP; Krieg JC
J Bone Joint Surg Am; 2014 Nov; 96(22):1905-9. PubMed ID: 25410509
[TBL] [Abstract][Full Text] [Related]
37. Bone Structure and Turnover Status in Postmenopausal Women with Atypical Femur Fracture After Prolonged Bisphosphonate Therapy.
Qiu S; Divine GW; Palnitkar S; Kulkarni P; Guthrie TS; Honasoge M; Rao SD
Calcif Tissue Int; 2017 Mar; 100(3):235-243. PubMed ID: 28013363
[TBL] [Abstract][Full Text] [Related]
38. Fracture Risk Following an Atypical Femoral Fracture.
Bégin MJ; Audet MC; Chevalley T; Portela M; Padlina I; Hannouche D; Ing Lorenzini K; Meier R; Peter R; Uebelhart B; Rizzoli R; Ferrari S; Biver E
J Bone Miner Res; 2022 Jan; 37(1):87-94. PubMed ID: 34668223
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates and atypical femoral fractures.
Adler RA
Curr Opin Endocrinol Diabetes Obes; 2016 Dec; 23(6):430-434. PubMed ID: 27653003
[TBL] [Abstract][Full Text] [Related]
40. Are race and sex associated with the occurrence of atypical femoral fractures?
Marcano A; Taormina D; Egol KA; Peck V; Tejwani NC
Clin Orthop Relat Res; 2014 Mar; 472(3):1020-7. PubMed ID: 24166075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
